NFE2L2 and neoplasm: Immunoblotting of tumor xenografts indicated that NRF2 expression was reduced to 60%, NQO1 to 72%, AKR1C to 55%, and HO-1 to 58% in the luteolin and combination treatments, whereas there was no significant reduction in the cisplatin group.